Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease, but the response to antiviral therapy among African Americans is much lower than among whites. We will study how therapy affects the HCV genome and HCV RNA synthesis activity in African Americans and whites to understand this difference.
Aim l: What variations are present in the complete HCV genomes of viruses infecting African Americans and whites? We hypothesize that viral variants that are less responsive to antiviral therapy are found disproportionately in African Americans. Therefore, we will sequence the entire HCV genome from 50 African Americans and 50 whites both before and after treatment. We will then align the sequences and look for differences that correlate with racial group and/or with response to antiviral therapy.
Aim 2 : How does the quasi-species distribution of the HCV genome vary in response to therapy? We hypothesize that therapy selects for HCV variants that are less susceptible to therapy. We will analyze quasi- species variation in 10 responders prior to therapy and in 10 non- responders both prior to and after therapy (half African Americans and half whites). Twenty isolates from each of the 5 regions that vary the most between the pre- and posttreatment samples in Aim 1 will be cloned and sequenced. We will look for common patterns of HCV genetic drift following failure of therapy and for differences in quasi- species distribution between the African Americans and whites.
Aim 3 : How does HCV RNA synthesis vary in response to therapy? We hypothesize that variations in the HCV RNA polymerase (RdRp) can alter RNA replication and affect response to therapy. We will assess the ability of the RdRps from each of the patients in Aim 1 before and after therapy to synthesize RNA. We will determine if RdRp activity correlates with response to therapy and how RNA synthesis changes with variation in the RdRp. These studies will provide a complete view of the HCV genome during therapy, will provide basic information about RNA replication, and will identify viral factors underlying response to therapy in African Americans and whites. This may improve treatment or guide development of new therapies for both racial groups.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK060345-03
Application #
6647593
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M3))
Program Officer
Robuck, Patricia R
Project Start
2001-08-01
Project End
2006-04-30
Budget Start
2003-07-01
Budget End
2004-04-30
Support Year
3
Fiscal Year
2003
Total Cost
$275,000
Indirect Cost
Name
Saint Louis University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
050220722
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Terrault, Norah A; Dodge, Jennifer L; Murphy, Edward L et al. (2013) Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 57:881-9
Jin, Runyan; Cai, Ling; Tan, Ming et al. (2012) Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Am J Gastroenterol 107:1675-83
Howell, Charles D; Gorden, Alexis; Ryan, Kathleen A et al. (2012) Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol 56:557-63
Golden-Mason, Lucy; Bambha, Kiran M; Cheng, Linling et al. (2011) Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54:1559-69
Evon, Donna M; Esserman, Denise A; Ramcharran, Darmendra et al. (2011) Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res 71:349-56
Conjeevaram, Hari S; Wahed, Abdus S; Afdhal, Nezam et al. (2011) Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 140:469-77
Donlin, Maureen J; Cannon, Nathan A; Aurora, Rajeev et al. (2010) Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 5:e9032
Evon, Donna M; Ramcharran, Darmendra; Belle, Steven H et al. (2009) Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 104:2949-58
Yee, L J; Im, K; Borg, B et al. (2009) Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 10:365-72
Aurora, Rajeev; Donlin, Maureen J; Cannon, Nathan A et al. (2009) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 119:225-36

Showing the most recent 10 out of 33 publications